Indications and uses
GLOFIL ® -125 (Sodium Iothalamate I-125 Injection) is indicated for evaluation of glomerular filtration in the diagnosis or monitoring of patients with renal disease.
GLOFIL-125 - QOL Medical
- Manufacturer
- QOL Medical
- Effective date
- 2007-06-23
- Label type
- HUMAN PRESCRIPTION DRUG LABELING
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-05-31 20:06:57
Label at a glance#
ProductGLOFIL-125
Label structure9 sections
Dosage and administration
The suggested dose range employed in the average patient (70 kg) is as follows: Continuous intravenous infusion: 20 to 100 μCi (0.74-3.7 megabecquerels) (Sigman, et al ( 1 ) method). Single intravenous injection: 10 to 30 μCi (0.37-1.11 megabecquerels) (Cohen, et al ( 2 ) method). The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. Sig...
Contacts and useful links#
Label contents#
Full prescribing information#
DESCRIPTION
General
GLOFIL®-125 (Sodium Iothalamate I-125 Injection) is a sterile, nonpyrogenic aqueous injection containing approximately 1 mg sodium iothalamate per mL, and 0.9 percent benzyl alcohol as a preservative. The radioactive concentration of the material is 250-300 μCi/mL as of the calibration date. Sodium bicarbonate and hydrochloric acid are present for pH adjustment.
Physical Characteristics
Iodine-125 decays by electron capture with a physical half-life of 60.14 days. Photons that are useful for detection are listed in Table 1.
| Radiation | Mean Number Per Disintegration | Mean Energy (keV) |
| Gamma-1 | 0.067 | 35.5 |
| Kα1 X-ray | 0.741 | 27.5 |
| Kα2 X-ray | 0.398 | 27.2 |
| Kß1 X-ray | 0.140 | 31.0 |
| Kß2 X-ray | 0.043 | 31.7 |
| Kß3 X-ray | 0.072 | 30.9 |
* ICRP Publication 38: Radionuclide Transformations - Energy and Intensity of Emissions. Published for the International Commission on Radiological Protection by Pergamon Press, New York, 1983, p. 446.
The specific gamma ray constant for I-125 is 1.43 R/mCi-hr at 1 cm. The first half value thickness of lead (Pb) for I-125 is 0.017 mm. A range of values for the relative attenuation of the radiation emitted by this radionuclide resulting from interposition of various thicknesses of Pb is shown in Table 2. For example, the use of 0.28 mm of Pb will decrease the external radiation exposure by a factor of 10,000.
| Shield Thickness (Pb), mm | Coefficient of Attenuation |
| 0.017 | 0.5 |
| 0.058 | 0.1 |
| 0.12 | 0.01 |
| 0.2 | 0.001 |
| 0.28 | 0.0001 |
* Data supplied by Oak Ridge Associated Universities, Radiopharmaceutical Internal Dose Information Center, Oak Ridge, TN 1989.
To correct for physical decay of this radionuclide, the fractions that remain at selected time intervals after the date of calibration are shown in Table 3.
| Days | Fraction Remaining | Days | Fraction Remaining | Days | Fraction Remaining |
| 0* | 1.000 | 15 | 0.841 | 30 | 0.707 |
| 1 | 0.989 | 16 | 0.831 | 31 | 0.699 |
| 2 | 0.977 | 17 | 0.822 | 32 | 0.691 |
| 3 | 0.966 | 18 | 0.812 | 33 | 0.683 |
| 4 | 0.955 | 19 | 0.803 | 34 | 0.675 |
| 5 | 0.944 | 20 | 0.794 | 35 | 0.667 |
| 6 | 0.933 | 21 | 0.785 | 36 | 0.660 |
| 7 | 0.922 | 22 | 0.776 | 37 | 0.652 |
| 8 | 0.912 | 23 | 0.767 | 38 | 0.645 |
| 9 | 0.901 | 24 | 0.758 | 39 | 0.637 |
| 10 | 0.891 | 25 | 0.749 | 40 | 0.630 |
| 11 | 0.881 | 26 | 0.740 | 41 | 0.623 |
| 12 | 0.871 | 27 | 0.732 | 42 | 0.616 |
| 13 | 0.861 | 28 | 0.724 | 43 | 0.608 |
| 14 | 0.851 | 29 | 0.715 | 44 | 0.601 |
| 45 | 0.595 |
* Calibration Date
CLINICAL PHARMACOLOGY
The renal clearance of sodium iothalamate in man closely approximates that of inulin. The compound is cleared by glomerular filtration without tubular secretion or reabsorption. Following infusion administration of I-125 iothalamate, the effective half-life is about 0.07 days.
INDICATIONS AND USAGE
GLOFIL®-125 (Sodium Iothalamate I-125 Injection) is indicated for evaluation of glomerular filtration in the diagnosis or monitoring of patients with renal disease.
CONTRAINDICATIONS
GLOFIL®-125 should not be administered via a central venous line.
WARNINGS
None known.
PRECAUTIONS
General
As in the use of any radioactive material, care should be taken to minimize radiation exposure to the patient, consistent with proper patient management, and to insure minimum radiation exposure to occupational workers.
Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides.
Rapid or bolus-like injections should be avoided.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No long-term animal studies have been performed to evaluate carcinogenic potential, mutagenic potential, or whether this drug affects fertility in males or females.
Pregnancy Category C
Animal reproduction studies have not been conducted with GLOFIL®-125. It is also not known whether GLOFIL®-125 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. GLOFIL®-125 should be given to a pregnant woman only if clearly needed.
Nursing Mothers
Radioiodine is excreted in human milk during lactation. It is not known whether GLOFIL®-125 is excreted in human milk. Therefore, formula feedings should be substituted for breast feedings.
Pediatric Use
Safety and effectiveness in children have not been established.
ADVERSE REACTIONS
None reported.
DOSAGE AND ADMINISTRATION
Dosage
The suggested dose range employed in the average patient (70 kg) is as follows:
Continuous intravenous infusion: 20 to 100 μCi (0.74-3.7 megabecquerels) (Sigman, et al (1) method).
Single intravenous injection: 10 to 30 μCi (0.37-1.11 megabecquerels) (Cohen, et al (2) method).
The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.
Technique
Continuous intravenous infusion
Sigman (1) method
I. Preparation:
- Adequate diuresis (a urine flow exceeding 3 mL/min.) is established, preferably by an oral water load of 1,500 mL two hours prior to the beginning of the clearance study.
- It is not necessary to withhold breakfast or admit the patient the night before.
II. Procedure:
- After the establishment of adequate diuresis, a number 14 or 16 French Foley catheter is aseptically inserted into the bladder.
- An intravenous infusion of Lactated Ringer’s (Hartmann’s) solution is started in each arm, one to maintain a site for injection of the GLOFIL®-125, the other to serve as a site for serial withdrawal of blood. A two-way stopcock connects the needle and intravenous tubing of each arm.
- The dose is equally divided into (1) an intravenous priming dose to be injected as is and (2) a sustaining dose to be diluted in 30 to 60 mL of isotonic sodium chloride, depending on how many collection periods are anticipated.
- The priming dose is slowly injected into one arm. This is immediately followed by infusion of the sustaining solution through the same site, usually at the rate of 0.5 mL/min., by means of an automatic pump. During this infusion, the Lactated Ringer’s solution in the same arm is discontinued, and 40 to 45 minutes are allowed for equilibration in order to reach a state of constant plasma concentration of radioactivity.
- After attaining equilibrium, consecutive 15 minute collection periods are started. From the arm opposite the injection site, 5 mL of blood (allowing duplicate plasma counting volumes) is drawn six minutes prior to the midpoint of each collection period, placed in heparinized tubes, mixed, and centrifuged. The blood samples may be obtained through the two-way stopcock after discarding the first 30 mL aspirated into the syringe. This 30 mL contains the contents of the tubing, including infusion fluid, and must be cleared in order to obtain an undiluted blood sample. If desired, this step may be eliminated and blood samples obtained by direct venipuncture.
- During each collection period, total urine must be accurately collected and the volume accurately measured. Three such consecutive collection periods are sufficient for most clinical studies.
III. Clearance Calculations:
- Aliquots (1 mL each) of plasma and urine from each collection period are counted in a standard gamma-ray scintillation well detector.
- All counts are corrected for background activity.
- Glomerular filtration rate is calculated by the formula C=UV/P, in which:
C = glomerular filtration rate in mL/min
U= urinary concentration of radioactivity in net counts/min/mL
V= urinary flow rate in mL/min
P = plasma concentration of radioactivity in net counts/min/mL - Average glomerular filtration rate (GFR) is calculated from the rates for the individual collection periods. GFR can be expressed in terms of body weight (mL/min/kg) or body surface area (mL/min/m2).
- Unilateral glomerular filtration rates can be determined by the same technique by utilizing ureteral catheterization.
Single intravenous injection
Cohen (2) method:
The method of Cohen, et al (2) requires little preparation, few and small blood samples, no bladder catheterization, and no constant intravenous infusion. It is simple to perform, rapid, and utilizes equipment which is readily available in most modern laboratories.
I. Preparation:
-
Lugol's solution, 3 drops orally, three times a day, is administered
for one or two days prior to the test.
No diet or water restriction is necessary.
- Oral water load is begun one hour before starting the test. Start with 20 mL/kg and force any clear liquids (unless contraindicated) until the test is complete.
II. Procedure: Record actual times for the collection of the blood and urine samples.
- Empty the bladder and label the urine Urine control.
- Inject 10-30 μCi GLOFIL®-125 intravenously; wait 30 to 60 minutes.
- Collect the entire urine and label Urine discard.
- Draw 4 to 5 mL of blood into a heparinized syringe. Label Plasma #1.
- After another 30 to 60 minutes, collect the entire urine and label Urine #1.
- Immediately draw another blood specimen. Label Plasma #2.
- After final 30 to 60 minute wait, collect the urine. Label Urine #2.
- Draw the last blood specimen immediately. Label Plasma #3.
III. Clearance Calculations:
- Radioactivity of one mL aliquots of both urine and plasma are determined using a well-scintillation detector with a single channel pulse-height analyzer. Sufficiently reproducible counts are usually obtained with time settings of 2 minutes for urine samples and 20 minutes for the plasma samples. Calculations of the clearance rates are made by using the formula:(1)
C = UV/P + 1.73/SA where
C = glomerular filtration rate in mL/min/1.73 m2
U = urine radioactivity in counts/min/mL
V = urine flow rate in mL/min
P= mean plasma radioactivity in counts/min/mL
SA= body surface area in m2
Radiation Dosimetry
The estimated absorbed radiation doses to an average (70 kg) patient from an intravenous dose of 100 μCi (3.7 megabecquerels) of GLOFIL®-125 are shown in Table 4. Calculations assume that there is 1% free iodide in the preparation and that the thyroid uptake of the iodine is 25%.
| Absorbed radiation doses for 100 µCi (3.7 megabecquerels) | ||||
| 2 hour bladder voiding interval | 4.8 hour bladder voiding interval | |||
| Organ | rads | mGy | rads | mGy |
| Lower Large Intestine Wall | 0.00065 | 0.0065 | 0.0012 | 0.012 |
| Small Intestine | 0.00044 | 0.0044 | 0.00050 | 0.0050 |
| Stomach | 0.00047 | 0.0047 | 0.00047 | 0.0047 |
| Upper Large Intestine Wall | 0.00040 | 0.0040 | 0.00044 | 0.0044 |
| Kidneys | 0.0064 | 0.064 | 0.0064 | 0.064 |
| Liver | 0.0018 | 0.018 | 0.0018 | 0.018 |
| Ovaries | 0.00054 | 0.0054 | 0.00085 | 0.0085 |
| Testes | 0.0019 | 0.019 | 0.0021 | 0.021 |
| Urinary Bladder Wall | 0.022 | 0.22 | 0.06 | 0.6 |
| Red Marrow | 0.00033 | 0.0033 | 0.00034 | 0.0034 |
| Thyroid | 0.78 | 7.8 | 0.78 | 7.8 |
| Total Body | 0.00096 | 0.0096 | 0.0011 | 0.011 |
* Data supplied by Oak Ridge Associated Universities, Radiopharmaceutical Internal Dose Information Center, Oak Ridge, TN, 1988.
Visual Inspection
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
HOW SUPPLIED
Identity
No. 1000, GLOFIL®-125 is a clear, colorless, sterile, and nonpyrogenic solution available as a 4 mL vial. It is supplied in a concentration of approximately 1 mg/mL sodium iothalamate (range is 0.5–2.0 mg sodium iothalamate per mL), with a radioactivity concentration of 250 to 300 μCi/mL at the time of calibration. Benzyl alcohol 0.9%, is added as a preservative. Sodium bicarbonate and hydrochloric acid are added for pH adjustment. The calibration and expiration dates are shown on the label.
Storage
Refrigerate the product upon receipt at 2°C to 8°C.
Dose Volume Calculation
Table 3 provides the required factors for the determination of activity per mL post calibration date for GLOFIL®-125 sterile solution.
To determine the dose volume, locate the decay factor (fraction remaining) which corresponds to the day that the dose is to be administered. The following equation is then utilized to determine the dose volume:
(activity of desired dose) /[(decay factor) x (amount of activity/mL on calibration day)] = dose volume (mL) (information on label)
REFERENCES
- Sigman EM, Elwood CM, Reagan ME, Morris AM, Catanzaro A. The renal clearance of 131I labeled sodium iothalamate in man. Invest Urol 1965; 2:432.
- Cohen ML, Smith FG Jr., Mindell RS, Vernier RL. A simple reliable method of measuring glomerular filtration rate using single low dose sodium iothalamate 131I.Pediatrics 1969; 43:407.
ADDITIONAL REFERENCES
- Maher FT, Nolan NG, Elveback LR. Comparisons of simultaneous clearances of 125I-labeled sodium iothalamate (Glofil) and of Inulin. Mayo Clin Proc 1971; 46: 690-691.
- Skov PE. Glomerular filtration rate in patients with severe and very severe renal insufficiency. Acta Med Scand 1970; 187: 419-428.
SPL UNCLASSIFIED SECTION
Manufactured by Iso-Tex Diagnostics, Inc. for QOL Medical
QOL Medical
Kirkland, WA 98033
Phone 1-866-469-3773
Revised April 2006
No. 1000
NDC 67871-772-92
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| fb7ab793-2c12-4079-b100-a64f73bef25a | Product name | 4 | 20240712 |
| b0cbf770-6cc3-4aa4-9158-755110c2b9f7 | Product name | 2 | 20230717 |
| dc7c5daa-021f-40dd-b00d-63982cb2067a | Product name | 1 | 20230426 |
| 08ffbcbf-26df-b99c-1dab-64fc4cfae89f | Product name | 5 | 20200925 |
| 816b97af-edc5-4060-aff1-b814bdbcad50 | Product name | 1 | 20190415 |
| 7cda52fc-125f-421c-8fea-bc1974370c49 | Product name | 2 | 20180703 |
| 419aab54-5d5a-4146-9453-026d4a9991be | Product name | 2 | 20170525 |
| 08ffbcbf-26df-b99c-1dab-64fc4cfae89f | Product name | 2 | 20160823 |
| 89dac932-b90a-4410-9ab1-84c53e57de25 | Product name | 1 | 20150316 |
| 9869efd7-d6dd-0665-5b67-53adbe6ef15e | Product name | 1 | 20140508 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Iothalamate sodium, I-125 | ACTIVE INGREDIENT | 31J5U3Q9ZN | 1 | |
| Iothalamate sodium, I-125 | ACTIVE MOIETY | 31J5U3Q9ZN | 1 | |
| benzyl alcohol | INACTIVE INGREDIENT | LKG8494WBH | 1 | |
| hydrochloric acid | INACTIVE INGREDIENT | QTT17582CB | 1 | |
| sodium bicarbonate | INACTIVE INGREDIENT | 8MDF5V39QO | 1 |
Products#
Every source-derived product name is available through these pages.
- GLOFIL-125
- Iothalamate sodium, I-125
- benzyl alcohol
- sodium bicarbonate
- hydrochloric acid
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 67871-772 | 67871-772-92 |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRABURSAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SOLUTION / SUBMUCOSAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / URETHRAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION / SUBCUTANEOUS | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | CAPSULE, LIQUID FILLED / ORAL | ADJ PH | ||
| benzyl alcohol | BENZYL ALCOHOL | LKG8494WBH | INJECTION / INTRAVENOUS | 1620 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | GEL, METERED / TOPICAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRADERMAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SUSPENSION / INTRALESIONAL | ADJ PH | ||
| benzyl alcohol | BENZYL ALCOHOL | LKG8494WBH | GEL / TOPICAL | 185 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | AEROSOL, FOAM / TOPICAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRAMUSCULAR | 306 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRAVENOUS | 720 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | LIQUID / ORAL | 4.46 mg/1ml | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRA-ARTERIAL | 840 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INFILTRATION | 0.37 %w/v | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | LOTION / TOPICAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SOLUTION / SUBCUTANEOUS | 1037 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | EMULSION / TOPICAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION, CONCENTRATE / INTRAVENOUS | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, EMULSION / INTRAVENOUS | ADJ PH | ||
| sodium bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, EFFERVESCENT / ORAL | 57600 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / PERINEURAL | ADJ PH | ||
| sodium bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 3059 mg | ||
| benzyl alcohol | BENZYL ALCOHOL | LKG8494WBH | INJECTION, EMULSION / SUBCUTANEOUS | 225 mg | ||
| sodium bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | SOLUTION / ORAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / IRRIGATION | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | AEROSOL, METERED / RESPIRATORY (INHALATION) | 0.7 %w/w | ||
| benzyl alcohol | BENZYL ALCOHOL | LKG8494WBH | LOTION / TOPICAL | 4000 mg | ||
| benzyl alcohol | BENZYL ALCOHOL | LKG8494WBH | SOLUTION / INTRAMUSCULAR | 54 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRALESIONAL | ADJ PH | ||
| sodium bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION / SUBCUTANEOUS | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | CREAM / TOPICAL | 38 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SUSPENSION / SUBCUTANEOUS | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | CONCENTRATE / ORAL | 2.17 mg/1ml | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / INTRAPERITONEAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | LIQUID / INTRAMUSCULAR | ADJ PH | ||
| benzyl alcohol | BENZYL ALCOHOL | LKG8494WBH | CREAM / VAGINAL | 1 %w/w | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 4.17 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / RETROBULBAR | ADJ PH | ||
| sodium bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 1000 mg | ||
| benzyl alcohol | BENZYL ALCOHOL | LKG8494WBH | SUSPENSION / AURICULAR (OTIC) | 0.9 %w/v | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / INTRAMUSCULAR | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | POWDER / INTRAVENOUS | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / EXTRACORPOREAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / ORAL | 223 mg | ||
| sodium bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | GUM, CHEWING / ORAL | 360 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SUSPENSION / INTRAMUSCULAR | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| sodium bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | FILM, SOLUBLE / ORAL | 2 mg | ||
| sodium bicarbonate | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 6 mg | ||
| benzyl alcohol | BENZYL ALCOHOL | LKG8494WBH | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 8.4 mg | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / PARENTERAL | ADJ PH | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / AURICULAR (OTIC) | 0.37 %w/v | ||
| hydrochloric acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / ENDOTRACHEAL | ADJ PH |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 5680FB25-E286-2B0D-DBCD-A28D53D2B8F0 | 2C07CE91-CC83-45e3-BD2B-F923A9C8286C | 2007-06-23 | Warnings, Adverse reactions | 5680FB25-E286-2B0D-DBCD-A28D53D2B8F0 2C07CE91-CC83-45e3-BD2B-F923A9C8286C |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.